

# Benjamin Rolland

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6542638/benjamin-rolland-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146  
papers

2,560  
citations

24  
h-index

45  
g-index

200  
ext. papers

3,254  
ext. citations

4  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
146	Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> ,	18.8	1
145	Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. <i>CNS Spectrums</i> , <b>2021</b> , 26, 459-467	1.8	3
144	Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 220, 108492	4.9	3
143	Validation of the French version of the Cannabis Use Disorder Identification Test-Revised and comparison with the Cannabis Abuse Screening Test for screening cannabis use disorder in a psychiatric sample. <i>Drug and Alcohol Review</i> , <b>2021</b> , 40, 1334-1339	3.2	0
142	Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 519-529	14.5	14
141	Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. <i>Patient Preference and Adherence</i> , <b>2021</b> , 15, 1259-1267	12.7	3
140	Psychological Distress and Tobacco Use Among Hospital Workers During COVID-19. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 701810	5	1
139	Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN). <i>Therapie</i> , <b>2021</b> , 76, 127-136	3.8	2
138	Social cognition in severe alcohol use disorder <b>2021</b> , 175-199		
137	Religiosity and prevalence of suicide, psychiatric disorders and psychotic symptoms in the French general population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2021</b> , 271, 1547-1557	5.1	3
136	The Early Impact of the COVID-19 Lockdown on Stress and Addictive Behaviors in an Alcohol-Consuming Student Population in France. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 628631	5	14
135	Analgesic opioid use disorders in patients with chronic non-cancer pain: A holistic approach for tailored management. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 121, 160-174	9	1
134	Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features. <i>CNS Drugs</i> , <b>2021</b> , 35, 177-213	6.7	1
133	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2021</b> , 45, 1722-1734	3.7	3
132	Usages et bon usage des benzodiazépines anxiolytiques et hypnotiques. <i>Annales Medico-Psychologiques</i> , <b>2021</b> , 179, 748-748	0.2	1
131	Tobacco-induced sleep disturbances: A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , <b>2021</b> , 60, 101544	10.2	3
130	Peer Role-Play for Training Communication Skills in Medical Students: A Systematic Review. <i>Simulation in Healthcare</i> , <b>2020</b> , 15, 106-111	2.8	9

129	Prolonged-release buprenorphine formulations: Perspectives for clinical practice. <i>Therapie</i> , <b>2020</b> , 75, 397-406	3.8	8
128	Alcohol Use Disorder Is Differently Associated With Psychotic Symptoms According To Underlying Psychiatric Disorders: A General Population Study. <i>Alcohol and Alcoholism</i> , <b>2020</b> , 55, 112-120	3.5	1
127	Global Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and Substance Use During the Early COVID-19 Containment Phase in the General Population in France: Survey Study. <i>JMIR Public Health and Surveillance</i> , <b>2020</b> , 6, e19630	11.4	139
126	Depression with and without a history of psychotic symptoms in the general population: sociodemographic and clinical characteristics. <i>Journal of Affective Disorders</i> , <b>2020</b> , 273, 247-251	6.6	7
125	Management of insomnia in alcohol use disorder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 297-3064		11
124	Alterations in circadian rhythms following alcohol use: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 99, 109831	5.5	13
123	France Grants an Approval to Baclofen for Alcohol Dependence. <i>Alcohol and Alcoholism</i> , <b>2020</b> , 55, 44-45	3.5	6
122	Disparate regulatory status of methylphenidate for adults with ADHD across Europe. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, e1-e2	23.3	2
121	A Latent Class Analysis of Manic and Psychotic Symptoms. <i>Journal of Nervous and Mental Disease</i> , <b>2020</b> , 208, 721-728	1.8	3
120	The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2020</b> , 118, 121-133	9	7
119	Hostile attributional bias in severe alcohol use disorder. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 129, 176-180	3.0	5
118	Respective influence of current alcohol consumption and duration of heavy drinking on brain morphological alterations in alcohol use disorder. <i>Addiction Biology</i> , <b>2020</b> , 25, e12751	4.6	8
117	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). <i>Addiction</i> , <b>2020</b> , 115, 573-582	4.6	7
116	France removes hepatitis C treatment prescriber restrictions-But what is the impact of the delay for key populations?. <i>Liver International</i> , <b>2019</b> , 39, 2418-2419	7.9	1
115	What place for prolonged-release buprenorphine depot-formulation Buvidal <sup>®</sup> in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. <i>Expert Opinion on Drug Delivery</i> , <b>2019</b> , 16, 907-914	8	18
114	Role of Patient Sex in Early Recovery from Alcohol-Related Cognitive Impairment: Women Penalized. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	2
113	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 61-68	5.5	10
112	Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 627	5.6	21

111	Animal Models of Binge Drinking: Behavior and Clinical Relevance <b>2019</b> , 57-66		1
110	Impulsivity and Binge Drinking: A Neurocognitive Perspective <b>2019</b> , 335-343		0
109	Dose-dependent metabolite changes after ethanol intoxication in rat prefrontal cortex using in vivo magnetic resonance spectroscopy. <i>Scientific Reports</i> , <b>2019</b> , 9, 10682	4.9	1
108	Baclofen and other GABA-B agonists for alcohol use disorders: An international perspective. <i>French Journal of Psychiatry</i> , <b>2019</b> , 1, S27-S28	0.1	
107	A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France. <i>Therapie</i> , <b>2019</b> , 74, 645-650	3.8	1
106	Barriers and levers in screening and care for alcohol use disorders among French general practitioners: results from a computer-assisted telephone interview-based survey. <i>Alcoholism Treatment Quarterly</i> , <b>2019</b> , 37, 207-224	1.2	2
105	A Patient-Tailored Evidence-Based Approach for Developing Early Neuropsychological Training Programs in Addiction Settings. <i>Neuropsychology Review</i> , <b>2019</b> , 29, 103-115	7.7	24
104	Animal models of binge drinking, current challenges to improve face validity. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 106, 112-121	9	19
103	Evaluation by undergraduate medical students of a role-playing training program on the management of acute states of agitation. <i>L'Encephale</i> , <b>2018</b> , 44, 101-105	2.9	3
102	Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 187, 40-47	4.9	73
101	Increased prevalence of anxiety disorders in third-generation migrants in comparison to natives and to first-generation migrants. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 102, 38-43	5.2	15
100	The need for patient-tailored dosing of baclofen in future clinical trials. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 656-657	1.2	3
99	Sociodemographic and clinical correlates of psychotic symptoms in the general population: Findings from the MHGP survey. <i>Schizophrenia Research</i> , <b>2018</b> , 193, 336-342	3.6	25
98	A study in the general population about sadness to disentangle the continuum from well-being to depressive disorders. <i>Journal of Affective Disorders</i> , <b>2018</b> , 226, 66-71	6.6	20
97	Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 367	5	5
96	Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 385	5	6
95	Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study. <i>BMC Cancer</i> , <b>2018</b> , 18, 372	4.8	3
94	Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the 'Mental Health in General Population' (MHGP) survey. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2018</b> , 53, 567-576	4.5	17

93	Psychiatric comorbidities associated with a positive screening using the Montreal Cognitive Assessment (MoCA) test in subjects with severe alcohol use disorder. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 191, 266-269	4.9	6
92	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 708	5	28
91	A latent class analysis of psychotic symptoms in the general population. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2018</b> , 52, 573-584	2.6	14
90	On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies. <i>Fundamental and Clinical Pharmacology</i> , <b>2018</b> , 32, 234-238	3.1	4
89	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 957-960	23.3	60
88	How to Manage Self-Poisoning With Baclofen in Alcohol Use Disorder? Current Updates. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 417	5	7
87	Les symptômes thymiques liés à l'usage d'alcool. <i>Annales Medico-Psychologiques</i> , <b>2018</b> , 176, 813-818	0.2	1
86	Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 485	5	11
85	Prevalence and clinical severity of mood disorders among first-, second- and third-generation migrants. <i>Journal of Affective Disorders</i> , <b>2017</b> , 210, 174-180	6.6	21
84	Binge Drinking: Current Diagnostic and Therapeutic Issues. <i>CNS Drugs</i> , <b>2017</b> , 31, 181-186	6.7	25
83	Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France". <i>Drug Safety</i> , <b>2017</b> , 40, 361-362	5.1	
82	Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. <i>Hepatology</i> , <b>2017</b> , 66, 1464-1473	11.2	87
81	Troubles moteurs tardifs induits par antipsychotiques : mise au point. <i>Annales Medico-Psychologiques</i> , <b>2017</b> , 175, 474-479	0.2	
80	Alcohol Use Disorders and Immigration up to the Third Generation in France: Findings from a 39,617-Subject Survey in the General Population. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2017</b> , 41, 1137-1143	3.7	13
79	The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. <i>Human Psychopharmacology</i> , <b>2017</b> , 32, e2593	2.3	9
78	Comparison between the WHO and NIAAA criteria for binge drinking on drinking features and alcohol-related aftermaths: Results from a cross-sectional study among eight emergency wards in France. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 175, 92-98	4.9	10
77	Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 669-677	5.5	5
76	Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France. <i>Drug Safety</i> , <b>2017</b> , 40, 257-262	5.1	14

75	Thirty- Versus Ten-Day Diazepam Treatment for Alcohol Detoxification and a Comparison of Drinking Patterns, Craving, and Anxiety for up to 12 Weeks: A "Proof-of-Concept" Open-Label Randomized Controlled Trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 722-728	1.7	3
74	Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With More Buprenorphine. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 631-633	1.7	2
73	Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 1206-1214	2.2	8
72	Severity of Baclofen Self-Poisoning Linked to Psychiatric Co-morbidity in Alcohol-Dependent Patients: Better Measurement of Risk and Benefit. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 217-219	3.1	3
71	Binge Eating, But Not Other Disordered Eating Symptoms, Is a Significant Contributor of Binge Drinking Severity: Findings from a Cross-Sectional Study among French Students. <i>Frontiers in Psychology</i> , <b>2017</b> , 8, 1878	3.4	9
70	The Role of General Practitioners in the 2015 French Guidelines on Alcohol Misuse. <i>Alcohol and Alcoholism</i> , <b>2017</b> , 52, 747-748	3.5	1
69	Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 125-132	4.1	4
68	Buprenorphine dosing choices in specific populations: review of expert opinion. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1727-31	4	9
67	Factors Affecting the Agreement Between Emergency Psychiatrists and General Practitioners Regarding Involuntary Psychiatric Hospitalizations. <i>Scientific Reports</i> , <b>2016</b> , 6, 28134	4.9	0
66	Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 747-51	4.1	10
65	Characteristics of Patients with Alcohol Dependence Seeking Baclofen Treatment in France: A Two-Centre Comparative Cohort Study. <i>Alcohol and Alcoholism</i> , <b>2016</b> , 51, 664-669	3.5	11
64	Neonatal Abstinence Syndrome Following Tianeptine Dependence During Pregnancy. <i>Pediatrics</i> , <b>2016</b> , 137,	7.4	9
63	Catatonia and cannabis withdrawal: A case report. <i>Substance Abuse</i> , <b>2016</b> , 37, 188-9	3.8	15
62	The 2015 French guidelines on alcohol misuse, issued in partnership with the European Federation of Addiction Societies: a focus on children and adolescents. <i>European Child and Adolescent Psychiatry</i> , <b>2016</b> , 25, 1145-8	5.5	5
61	A Point-by-Point Response to Brillon. <i>CNS Neuroscience and Therapeutics</i> , <b>2016</b> , 22, 537-8	6.8	
60	Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. <i>CNS Neuroscience and Therapeutics</i> , <b>2016</b> , 22, 25-37	6.8	73
59	Does baclofen have antidepressant qualities?. <i>L'Encephale</i> , <b>2016</b> , 42, 384-5	2.9	3
58	Stratifying delays for assessment by type of substance to improve the probability of attendance in outpatient services. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 166, 187-93	4.9	

57	Is there really no evidence of the efficacy of brief alcohol interventions for increasing subsequent utilization of alcohol-related services? Commentary on the paper by Glass et al. (2015). <i>Addiction</i> , <b>2016</b> , 111, 180-1	4.6	2
56	Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1160-6; quiz 1167	0.7	92
55	Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France. <i>International Journal of Clinical Pharmacy</i> , <b>2015</b> , 37, 296-9	2.3	3
54	Interventions for Increasing Alcohol Treatment Utilization Among Patients with Alcohol Use Disorders from Emergency Departments: A Systematic Review. <i>Journal of Substance Abuse Treatment</i> , <b>2015</b> , 58, 6-15	4.2	11
53	Interventions for Increasing Subsequent Alcohol Treatment Utilisation Among Patients with Alcohol Use Disorders from Somatic Inpatient Settings: A Systematic Review. <i>Alcohol and Alcoholism</i> , <b>2015</b> , 50, 420-9	3.5	9
52	Behavior of 1 Ωresistors at frequencies below 1 Hz and the problem of assigning a dc value. <i>Metrologia</i> , <b>2015</b> , 52, 509-513	2.1	2
51	MARCO Diversit� des modalit�s de soins en psychiatrie p�natale. <i>European Psychiatry</i> , <b>2015</b> , 30, S72-S72	6	
50	The New French Guidelines on Alcohol Misuse: An Initiative for Strengthening Cross-European Interplay. <i>Addiction</i> , <b>2015</b> , 110, 1362-3	4.6	8
49	Dependence on Internet-Purchased Ethylphenidate. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 472-3	1.7	4
48	Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 291-9	1.3	68
47	Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. <i>International Clinical Psychopharmacology</i> , <b>2015</b> , 30, 49-53	2.2	20
46	Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1631-6	1.2	42
45	Les pratiques infirmi�res avanc�es : qu�est-ce que c�est ? Quel avenir pour les infirmiers de psychiatrie et d'addictologie ?. <i>European Psychiatry</i> , <b>2015</b> , 30, S5-S5	6	1
44	Effet longitudinal d'une administration aigu� d'ethanol sur le GABA et le glutamate : une �tude en spectroscopie par r�sonance magn�tique in vivo chez le rat. <i>European Psychiatry</i> , <b>2015</b> , 30, S116-S116	6	
43	Quelles strat�gies relationnelles pour aborder le m�susage d'alcool chez les patients atteints de troubles psychiatriques ?. <i>European Psychiatry</i> , <b>2015</b> , 30, S6-S7	6	
42	Attention-deficit/hyperactivity disorder (ADHD) in adults: Specific clinical and therapeutic issues. <i>European Psychiatry</i> , <b>2015</b> , 30, S27-S28	6	
41	The impact of discontinuing methylphenidate on weight and eating behavior. <i>International Journal of Eating Disorders</i> , <b>2015</b> , 48, 345-8	6.3	7
40	GABAB Agonists for the Treatment of Alcohol Use Disorder. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3367-72	3.3	23

39	Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3280-97	3.3	108
38	Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3359-66	3.3	16
37	Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 3298-305	3.3	8
36	Supervised injection services: what has been demonstrated? A systematic literature review. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 145, 48-68	4.9	261
35	Severe tinnitus induced by off-label baclofen. <i>Annals of Pharmacotherapy</i> , <b>2014</b> , 48, 656-9	2.9	16
34	Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 153-6	1.7	29
33	The System of Medical Treatment for Addiction in France. <i>International Journal of Mental Health</i> , <b>2014</b> , 43, 19-26	1.4	1
32	Acute and long-term effects of cannabis use: a review. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 4112-8	3.3	132
31	Final report on the on-going comparison BIPM.EM-K12: Comparison of quantum Hall effect resistance standards of the PTB and the BIPM. <i>Metrologia</i> , <b>2014</b> , 51, 01011-01011	2.1	6
30	The multimodal connectivity of the hippocampal complex in auditory and visual hallucinations. <i>Molecular Psychiatry</i> , <b>2014</b> , 19, 184-91	15.1	102
29	Pharmacology of hallucinations: several mechanisms for one single symptom?. <i>BioMed Research International</i> , <b>2014</b> , 2014, 307106	3	46
28	GPs and new compulsory admission procedures in France. <i>Psychiatric Services</i> , <b>2014</b> , 65, 271	3.3	8
27	Baclofen-induced edema in alcohol use disorders. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 478-81	2.9	9
26	Cortico-accumbens circuitry in schizophrenia: merely a "reward system"?. <i>Schizophrenia Research</i> , <b>2014</b> , 160, 233-4	3.6	2
25	Baclofen-induced manic symptoms: case report and systematic review. <i>Psychosomatics</i> , <b>2014</b> , 55, 326-332.6		32
24	Treatment of agitation in the emergency department: benzodiazepines could be safer than antipsychotics in some cases of insufficient medical data. <i>Journal of Emergency Medicine</i> , <b>2014</b> , 46, 830-1 <sup>1.5</sup>		9
23	Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. <i>PLoS ONE</i> , <b>2014</b> , 9, e98062	3.7	36
22	New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 4106-11	3.3	58



21	The need for developing preconception counseling in addiction medicine. <i>Archives of Women's Mental Health</i> , <b>2013</b> , 16, 433-4	5	3
20	Comment on: "Management of alcohol dependence in patients with liver disease". <i>CNS Drugs</i> , <b>2013</b> , 27, 863-4	6.7	1
19	Per-symptomatic brain activations in alcohol-induced hallucinosis. <i>Biological Psychiatry</i> , <b>2013</b> , 73, e13-4	7.9	1
18	Aripiprazole for treating cannabis-induced psychotic symptoms in ultrahigh-risk individuals. <i>Clinical Neuropharmacology</i> , <b>2013</b> , 36, 98-9	1.4	5
17	'Addiction' in adolescence: who is really losing control?. <i>Addiction</i> , <b>2013</b> , 108, 1516-7	4.6	1
16	Baclofen for alcohol-dependence: anticraving or partial substitution?. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 280-1	1.7	13
15	Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review. <i>Current Drug Targets</i> , <b>2013</b> , 14, 724-32	3	24
14	Sevrage ambulatoire : une expérience de la coopération en addictologie. <i>Soins Psychiatrie</i> , <b>2013</b> , 34, 38-42	0.1	2
13	Efficacy of aripiprazole in comorbid addiction in bipolar disorder. <i>CNS Neuroscience and Therapeutics</i> , <b>2012</b> , 18, 359-60	6.8	6
12	Early relapse in alcohol dependence may result from late withdrawal symptoms. <i>Medical Hypotheses</i> , <b>2012</b> , 79, 894-5	3.8	7
11	Alcohol-dependence: the current French craze for baclofen. <i>Addiction</i> , <b>2012</b> , 107, 848-9	4.6	49
10	Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2012</b> , 24, E37	2.7	3
9	The PPAR $\alpha$ Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia. <i>Schizophrenia Research and Treatment</i> , <b>2012</b> , 2012, 839853	0.6	14
8	Catatonia and alcohol withdrawal: a complex and underestimated syndrome. <i>Alcohol and Alcoholism</i> , <b>2012</b> , 47, 288-90	3.5	18
7	A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. <i>Alcohol and Alcoholism</i> , <b>2012</b> , 47, 577-80	3.5	32
6	Are gait initiation parameters early markers of Huntington's disease in pre-manifest mutation carriers?. <i>Gait and Posture</i> , <b>2011</b> , 34, 202-7	2.6	15
5	Shared vulnerability between seizures and psychosis in cocaine addiction?. <i>Epilepsy and Behavior</i> , <b>2011</b> , 22, 596-8	3.2	6
4	Pharmacological treatments for cocaine dependence: is there something new?. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 1359-68	3.3	44

3	Pharmaceutical approaches of binge drinking. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 1333-42	3-3	6
2	GABAergic and glutamatergic modulation in binge eating: therapeutic approach. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 1396-409	3-3	16
1	Global Changes and Factors of Increase in Caloric/Salty Food Intake, Screen Use, and Substance Use During the Early COVID-19 Containment Phase in the General Population in France: Survey Study (Preprint)		8